Latest News About Andes Virus

Here is the latest on Andes virus based on available public reporting up to now.

• General context: Andes virus is a hantavirus primarily carried by rodents in South America, with occasional human-to-human transmission reported in specific outbreaks. It can cause hantavirus pulmonary syndrome, which can be severe or fatal.[4][6]

• Notable recent developments:

  • Vaccination research: In 2024, UTMB reported progress with two mRNA vaccine candidates that protected against Andes virus in an animal model, suggesting potential for future vaccine development (no approved human vaccine exists yet). This work was highlighted in UTMB communications and related press coverage.[1][3]
  • Historical outbreak insights: Past analyses highlighted the 2018–2019 Epuyén outbreak in Argentina, where a single spillover event led to multiple human cases and demonstrated substantial transmission potential, underscoring the importance of PPE and infection control in healthcare settings. This event is frequently cited in review articles about Andes virus transmission dynamics.[2][4]

• Public health resources:

  • CDC hantavirus page provides background on Andes virus, transmission, and prevention measures for at-risk populations.[6]
  • Virology and surveillance literature continues to document genetic diversity of Andes virus strains across South America, including strains associated with outbreak events and their epidemiology.[9][4]

• What is uncertain or evolving:

  • There is no widely available, approved vaccine for Andes virus in humans as of now; prior vaccine efforts have shown promise in preclinical models but require human trials and regulatory approval.[3][1]
  • Ongoing outbreaks or new reports may emerge; keep an eye on major public health agencies (CDC, WHO) and reputable journals for updates.

Illustrative example:

• If a new outbreak occurred in a non-endemic setting, public health guidance would emphasize rapid case finding, contact tracing, use of PPE for healthcare workers, and genomic characterization to assess human-to-human transmission potential, consistent with lessons from Epuyén and related studies.[2][6]

If you’d like, I can narrow this to:

• a quick one-paragraph briefing for a briefing note,
• a timeline of major Andes virus events in the last decade,
• or a short list of reputable sources for ongoing monitoring.